Previous 10 | Next 10 |
Nasdaq said Wednesday it will delist shares of Waitr ( OTCQB:ASAP ), Calithera Biosciences ( OTC:CALA ), Statera Biopharma ( OTCPK:STAB ), Allied Healthcare Products ( OTC:AHPI ) and Tricida ( OTCPK:TCDAQ ). The exchange will also delist Eqonex ( OTCPK:EQOSQ ), Sco...
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolv...
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Conference Call November 14, 2022, 17:00 ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Confere...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. “Earlier in the fourt...
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Com...
Calithera Biosciences, Inc. ( NASDAQ: CALA ) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA ha...
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks. Among the biggest winners were penny stocks who...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will ...
Calithera Biosciences ( NASDAQ: CALA ) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 202...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
NASDAQ Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...